Article Details

Truist maintains $74 target on Tourmaline Bio stock amid market selloff - Investing.com

Retrieved on: 2024-04-17 19:11:54

Tags for this article:

Click the tags to see associated articles and topics

Truist maintains $74 target on Tourmaline Bio stock amid market selloff - Investing.com. View article details on HISWAI: https://www.investing.com/news/company-news/truist-maintains-74-target-on-tourmaline-bio-stock-amid-market-selloff-93CH-3382991

Summary

Truist Securities maintains its Buy rating on Tourmaline Bio despite a 60% stock drop, citing confidence in their biotech product TOUR006 compared to Roche's satralizumab, while noting Tourmaline's strong market liquidity and financial health.

Article found on: www.investing.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up